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Abstract
The nucleotide-binding-domain (NBD)–and leucine-rich repeat (LRR)–containing (NLR)
family, pyrin-domain–containing 3 (NLRP3) inflammasome drives pathological inflammation
in a suite of autoimmune, metabolic, malignant, and neurodegenerative diseases. Addition-
ally, NLRP3 gain-of-function point mutations cause systemic periodic fever syndromes that
are collectively known as cryopyrin-associated periodic syndrome (CAPS). There is signifi-
cant interest in the discovery and development of diarylsulfonylurea Cytokine Release Inhib-
itory Drugs (CRIDs) such as MCC950/CRID3, a potent and selective inhibitor of the NLRP3
inflammasome pathway, for the treatment of CAPS and other diseases. However, drug dis-
covery efforts have been constrained by the lack of insight into the molecular target and
mechanism by which these CRIDs inhibit the NLRP3 inflammasome pathway. Here, we
show that the NAIP, CIITA, HET-E, and TP1 (NACHT) domain of NLRP3 is the molecular
target of diarylsulfonylurea inhibitors. Interestingly, we find photoaffinity labeling (PAL) of
the NACHT domain requires an intact (d)ATP-binding pocket and is substantially reduced
for most CAPS-associated NLRP3 mutants. In concordance with this finding, MCC950/
CRID3 failed to inhibit NLRP3-driven inflammatory pathology in two mouse models of
CAPS. Moreover, it abolished circulating levels of interleukin (IL)-1β and IL-18 in lipopoly-
saccharide (LPS)-challenged wild-type mice but not in Nlrp3L351P knock-in mice and ex
vivo-stimulated mutant macrophages. These results identify wild-type NLRP3 as the molec-
ular target of MCC950/CRID3 and show that CAPS-related NLRP3 mutants escape efficient
MCC950/CRID3 inhibition. Collectively, this work suggests that MCC950/CRID3-based
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Introduction
Inflammasomes are a suite of multiprotein complexes that play central roles in innate immune
responses through their ability to recruit and activate caspase-1 (Casp1) [1,2]. This cysteine
protease cleaves the cytokines interleukin (IL)-1β and IL-18 and drives pyroptosis, a highly
inflammatory regulated cell death mode that is induced by cleavage of gasdermin D (GSDMD)
[3,4]. Among the different inflammasome pathways, the nucleotide-binding-domain (NBD)–
and leucine-rich-repeat (LRR)–containing (NLR) family, pyrin-domain–containing 3
(NLRP3) inflammasome responds to the broadest suite of inflammasome agonists that include
diverse pathogen-associated molecular patterns (PAMPs); host-derived danger-associated
molecular patterns (DAMPs) such as ATP; protein aggregates and β-fibrils such as β-amyloid;
a broad range of environmental insults and ionophores such as nigericin; and medically rele-
vant crystals such as alum, calcium pyrophosphate dihydrate (CPPD), monosodium urate
(MSU), silica, and asbestos [1,2]. Moreover, the NLRP3 inflammasome is engaged by gram-
negative pathogens, lipopolysaccharides (LPS) that are sensed in the cytosol by the non-canon-
ical NLRP3 inflammasome pathway [5–8]. Through the latter mechanism, cleavage of
GSDMD by caspase-11—and its human orthologs caspases 4 and 5—promotes assembly of
cytolytic GSDMD pores in the plasma membrane that also activate the NLRP3 inflammasome
to drive Casp1-dependent IL-1β and IL-18 maturation [3,5]. Consistent with the chemical
diversity of NLRP3 stimuli, activation of the NLRP3 inflammasome is thought to converge on
sensing of a secondary messenger or cellular state that is universally induced by NLRP3-acti-
vating agents [9].
Aberrant NLRP3 inflammasome activity is thought to contribute to the pathogenesis of
many chronic diseases, including inflammatory diseases such as gout and pseudogout; meta-
bolic diseases like atherosclerosis and nonalcoholic fatty liver disease (NAFLD)/nonalcoholic
steatohepatitis (NASH); and neurodegenerative diseases like Alzheimer’s disease, Parkinson’s
disease, and multiple sclerosis [10,11]. Moreover, gain-of-function mutations in and around
the central NAIP, CIITA, HET-E, and TP1 (NACHT) domain of NLRP3 cause three autoso-
mal dominantly inherited periodic fever syndromes that together are known as cryopyrin-
associated periodic syndrome (CAPS). Symptoms span a clinical spectrum, with Familial Cold
Autoinflammatory Syndrome (FCAS) being the mildest; Muckle–Wells syndrome (MWS)
being of moderate severity; and Neonatal Onset Multisystem Inflammatory Disease
(NOMID)/Chronic Infantile Neurological, Cutaneous, and Articular Syndrome (CINCA)
being the most severe form of CAPS, featuring systemic inflammation, neurological and sen-
sory impairment, and deforming arthropathy [12].
Selective and potent inhibitors of the NLRP3 inflammasome may have broad therapeutic
potential in CAPS and other diseases [10,11]. Early studies with the sulfonylurea drug glybur-
ide provided proof of concept that PAMP-, DAMP-, and crystal-induced activation of the
NLRP3 inflammasome pathway may be selectively targeted without interfering with other
inflammasome pathways [13]. The related diarylsulfonylurea compound MCC950/Cytokine
Release Inhibitory Drug 3 (CRID3) was originally reported as an inhibitor of IL-1β secretion
[14] and subsequently shown to potently and selectively inhibit the NLRP3 inflammasome
pathway in murine and human macrophages and monocytes with half maximal inhibitory
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concentration (IC50) values in the low nM range [15,16]. There is significant interest in the dis-
covery and development of diarylsulfonylurea CRIDs such as MCC950/CRID3 for the treat-
ment of CAPS and other diseases based on its ability to curb inflammatory pathology in
mouse models of CAPS, the experimental autoimmune encephalomyelitis mouse model of
multiple sclerosis, NAFLD/NASH, and many other inflammatory disease models [10,11].
However, the direct molecular target of MCC950/CRID3 in the NLRP3 inflammasome path-
way has remained elusive, hampering the rational optimization and development of MCC950/
CRID3-based therapies.
Utilizing two different chemoproteomic strategies, we here demonstrate that the NACHT
domain of NLRP3 is the molecular target of diarylsulfonylurea CRIDs. Interestingly, we find
photoaffinity labeling (PAL) of the NACHT domain of NLRP3 requires an intact (d)ATP-
binding pocket and is substantially reduced for most CAPS-associated NLRP3 mutants. In
accordance, NLRP3-driven inflammatory pathology in mouse models of CAPS was not effi-
ciently curbed by MCC950/CRID3. Consistently, MCC950/CRID3 abolished circulating levels
of IL-1β and IL-18 in LPS-challenged wild-type mice but not in CAPS mice and ex vivo-stimu-
lated mutant macrophages. These results identify the central NACHT domain of wild-type
NLRP3 as the molecular target of MCC950/CRID3 and show that CAPS-related NACHT
mutations prevent efficient MCC950/CRID3 inhibition. Collectively, this work suggests that
MCC950/CRID3-based therapies may effectively treat inflammation driven by wild-type
NLRP3 but not CAPS-associated mutants.
Results
MCC950/CRID3 selectively binds to human and murine NLRP3
As a first approach to identify the molecular target of MCC950/CRID3, we made use of PAL in
combination with click chemistry [17]. Guided by limited structure-activity studies, a cell-per-
meable photoaffinity probe was synthesized (Fig 1A, compound PAL-CRID3) that contains a
photoreactive benzophenone group to enable direct covalent labeling of MCC950/CRID3 tar-
gets upon exposure to UV light. The alkyne functionality in PAL-CRID3 allowed in situ click
reaction with a 5-carboxytetramethylrhodamine (TAMRA) fluorescent reporter to support in-
gel fluorescence detection of the covalent MCC950/CRID3-protein adduct by SDS-PAGE. A
dose–response analysis confirmed that PAL-CRID3 retained the ability to potently inhibit
NLRP3 inflammasome activation with submicromolar IC50 values. PAL-CRID3 inhibited
nigericin-induced IL-1β secretion from N-palmitoyl-S-dipalmitoylglyceryl Cys-Ser-(Lys)4
(Pam3CSK4)-primed primary bone-marrow–derived macrophages (BMDMs) (Fig 1B and S1
Data; IC50 = 731 nM) and estrogen-regulated homeobox protein Hox-B8 (ER-Hoxb8)–
immortalized macrophages (iMac) (Fig 1C and S1 Data; IC50 = 453 nM). As a reference,
MCC950/CRID3 inhibited nigericin-induced IL-1β secretion with IC50 values of 9 and 4 nM,
respectively (Fig 1B and 1C; S1 Data). We hypothesize that the lesser activity of PAL-CRID3
compared to MCC950/CRID3 is a combination of physical property and binding differences
that decrease target occupancy.
To screen candidate targets of MCC950/CRID3, HEK293T cells overexpressing Flag-epi-
tope–tagged fusions of the human inflammasome sensor proteins NLRP3, NLRP1, NLRC4,
NLRP6, and MEFV were incubated with PAL-CRID3 and exposed to UV light to allow cova-
lent binding of PAL-CRID3 to potential targets. Following cell lysis, the probe was conjugated
to the TAMRA reporter by click chemistry, and protein lysates were separated by SDS-PAGE.
Notably, in-gel fluorescence imaging showed significant TAMRA labeling of ectopically
expressed NLRP3 but not other inflammasome sensors in the panel (Fig 1D). To further
extend these findings, we next confirmed binding to murine Nlrp3 (Fig 1E). As controls,
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protein phosphatase PP1Cb and glutathione S-transferase GSTO1, which have been proposed
as the target of CRID compounds [14], were not labeled by PAL-CRID3 (Fig 1E). Moreover,
binding of PAL-CRID3 to human NLRP3 and murine Nlrp3 was only observed following UV
cross-linking, and labeling was rescued by competition with excess MCC950/CRID3 (Fig 1E),
thus ruling out nonspecific cross-linking and validating the specificity of these findings. To
further characterize the interaction of PAL-CRID3 with components of the NLRP3 inflamma-
some, we assessed binding to human never-in-mitosis-gene-a–related kinase 7 (NEK7), apo-
ptosis-associated speck-like protein (ASC), Casp1, and GSDMD. PAL-CRID3 failed to label
the NLRP3 inflammasome components in the panel apart from NLRP3 (Fig 1F). Collectively,
these results suggest that CRID compounds, including MCC950/CRID3, inhibit NLRP3
inflammasome signaling by directly binding to NLRP3.
To confirm and extend these findings to endogenous NLRP3, we made use of recently
described iBody technology to immobilize MCC950/CRID3 on polymers that enabled immu-
noprecipitation of MCC950/CRID3 targets [18]. In brief, MCC950/CRID3 was stochastically
modified with a photoactivatable phenyldiazirine linker, and the resulting isomeric mixture
was conjugated to a hydrophilic N-(2-hydroxypropyl)methacrylamide (HPMA) polymer back-
bone that is decorated with a biotin affinity tag (for details, please refer to the Materials and
Methods section and [18]). The MCC950/CRID3 iBody conjugate is further referred to as
iBody U121. The corresponding iBody conjugate lacking MCC950/CRID3 served as a negative
control and is referred to as iBody U126.
BMDMs of wild-type (C57BL/6J) and Nlrp3−/− mice were primed with LPS to transcrip-
tionally up-regulate NLRP3 inflammasome components [19], and cell lysates were subse-
quently incubated with iBody U121 (MCC950/CRID3) or iBody U126 (control), followed by
immunoprecipitation with streptavidin-coupled beads. Contrary to control iBody U126, iBody
U121 immunoprecipitated endogenous Nlrp3 from wild-type BMDMs (Fig 1G). iBody U121
failed to pull down inflammasome components ASC and Casp1 (Fig 1G). As expected, the
immunoreactive band was absent from immunoprecipitates and lysates of LPS-primed Nlrp3-
deficient macrophages (Fig 1G). Given the lack of suitable antibodies to detect endogenous
NLRC4, we made use of reported Nlrc43×Flag/3×Flag knock-in mice [20,21] to further validate
selective targeting of NLRP3. Consistent with our earlier results, only iBody U121 precipitated
endogenous Nlrp3 from LPS-primed Nlrc43×Flag/3×Flag BMDMs (Fig 1H). Comparable back-
ground binding of Nek7 was observed with iBody U121 and control iBody U126, whereas
Fig 1. MCC950/CRID3 directly targets NLRP3. (A) Chemical structure of MCC950/CRID3 and the photoaffinity probe PAL-CRID3. (B–C) LPS-primed
BMDMs (B) and iMac (C) were stimulated with Nig in presence of the indicated concentrations of MCC950/CRID3 or PAL-CRID3. Supernatants were analyzed
for IL-1β secretion. BMDM: IC50MCC950 = 0.009 μM; IC50PAL-CRID3 = 0.731 μM; iMac: IC50MCC950 = 0.004 μM; IC50PAL-CRID3 = 0.453 μM. (D) HEK293T cells
transfected with the indicated plasmids were incubated with PAL-CRID3 and subsequently irradiated. After cell lysis and click chemistry conjugation, lysates were
assayed by TAMRA imaging and by immunoblot analysis with the indicated antibodies. (E) HEK293T cells transfected with the indicated plasmids were
incubated with PAL-CRID3 in the absence or presence of free MCC950/CRID3 and subsequently irradiated (+ UV) or left untreated (no UV). After cells are
lysed, click chemistry is performed, and lysates were assayed by TAMRA imaging and by immunoblot analysis with the indicated antibodies. (F) HEK293T cells
transfected with the indicated plasmids were incubated with PAL-CRID3 and subsequently irradiated. After cells are lysed, click chemistry is performed, and
lysates are assayed by TAMRA imaging and by immunoblot analysis with the indicated antibodies. (G) Lysates of LPS-primed wild-type or Nlrp3-deficient
BMDMs were incubated with iBody U126 (Ctrl) or iBody U121 (MCC950/CRID3) and analyzed by pulldown assay with streptavidin agarose. Precipitates and
lysates were assayed by immunoblot analysis with the indicated antibodies. (H) Lysates of LPS-primed Nlrc4Flag/Flag BMDMs were incubated with iBody U126
(Ctrl) or iBody U121 (MCC950/CRID3), and lysates were analyzed by pulldown assay with streptavidin agarose. Precipitates and lysates were assayed by
immunoblot analysis with the indicated antibodies. The numerical values underlying Fig 1B and 1C can be found in S1 Data. Graphs show mean ± SD of triplicate
wells and represent three independent experiments. ASC, apoptosis-associated speck-like protein; BMDM, bone-marrow–derived macrophage; Casp1, caspase-1;
cmpd, compound; CRID, Cytokine Release Inhibitory Drug; Ctrl, control; ER-Hoxb8, estrogen-regulated homeobox protein Hox-B8; GSDMD, gasdermin D;
GSTO1, Glutathione S-transferase omega-1; HEK, human embryonic kidney; IC50, half maximal inhibitory concentration; IL, interleukin; iMac, ER-Hoxb8–
immortalized macrophages; LPS, lipopolysaccharides; LRR, leucine-rich repeat; MEFV, Mediterranean fever; NBD, nucleotide-binding domain; NEK7, never-in-
mitosis-gene-a–related kinase 7; Nig, nigericin; NLR, NBD- and LRR-containing; Nlrc4, NLR family, caspase-recruitment-domain–containing 4; NLRP3, NLR
family, pyrin-domain–containing 3; PAL, photoaffinity labeling; PP1Cb, protein phosphatase 1 catalytic subunit β isoform; TAMRA,
5-carboxytetramethylrhodamine; WB, western blot.
https://doi.org/10.1371/journal.pbio.3000354.g001
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neither Nlrc4 (detected using FLAG antibodies), Nek7, nor Pyrin were retrieved in iBody
U121 immunoprecipates of LPS-primed Nlrc4Flag/Flag BMDMs (Fig 1H). Collectively, these
results show that MCC950/CRID3 selectively binds to Nlrp3 in LPS-primed macrophages.
PAL-CRID3 targets the central NACHT domain of wild-type NLRP3 but
not CAPS mutants
NLRP3 consists of an amino-terminal Pyrin domain (PYD), a central NACHT domain, and
carboxy-terminal LRRs that are thought to lock NLRP3 in an inactive conformation. To map
the NLRP3 region(s) to which MCC950/CRID3 binds, we generated deletion mutants that
cover the following three regions of human NLRP3: (i) the N-terminal PYD; (ii) the central
NACHT domain (comprising the nucleotide-binding oligomerization domain (NOD) and
helical domain [HD] 2); and (iii) the carboxy-terminal LRR region (Fig 2A). Consistent with
our previous results (Fig 1), TAMRA analysis showed significant binding of PAL-CRID3 to
ectopically expressed full-length NLRP3 in HEK293T cells (Fig 2B). In addition, we observed
binding of PAL-CRID3 to the isolated NACHT (NOD + HD2) region of NLRP3 but not to the
PYD and LRR domains (Fig 2B). Labeling of both full-length NLRP3 and the isolated NACHT
region by PAL-CRID3 was rescued by treatment with an excess amount of free MCC950/
CRID3 (Fig 2B), confirming specificity and suggesting PAL-CRID3 and MCC950/CRID3
compete for the same binding site. Binding of ATP/dATP to the Walker A pocket in the
NACHT domain is essential for NLRP3 inflammasome assembly and function [22]. Interest-
ingly, mutation of the Walker A motif (GKT229/AAA) in full-length Nlrp3 abolished PAL-
CRID3 binding (Fig 2C), suggesting that an intact ATP-binding pocket is required for stron-
gest binding of diarylsulfonylurea CRID compounds.
The central NACHT domain of NLRP3 also contains most reported gain-of-function muta-
tions that cause CAPS disease (https://infevers.umai-montpellier.fr/web/index.php). This
prompted us to explore PAL-CRID3 binding to CAPS-associated NLRP3 mutants. Unexpect-
edly, introducing a random selection of 6 different CAPS mutations in the NACHT domain of
human NLRP3 that are associated with, respectively, MWS (NLRP3R325W, NLRP3R260L,
NLRP3A352V), FCAS (NLRP3A439V, NLRP3L305P), or NOMID (NLRP3R260P) all blunted bind-
ing of PAL-CRID3 to full-length human NLRP3 (Fig 2D). The classical MWS A352V and
FCAS L353P mutations in human NLRP3 correspond to the A350V and L351P mutations that
have been knocked into the murine Nlrp3 gene to model CAPS disease in mice [23]. Notably,
the Nlrp3A350V mutant did not significantly affect labeling by PAL-CRID3, whereas the
Nlrp3L351P mutation abolished labeling by PAL-CRID3 at 1 μM (Fig 2E). A dose–response
analysis showed that binding to the Nlrp3L351P mutant was also substantially affected with
higher (3 μM and 10 μM) PAL-CRID3 concentrations (Fig 2F). Together, these results suggest
that PAL of the NACHT domain requires an intact (d)ATP-binding pocket and is substantially
reduced for most CAPS-associated NLRP3 mutants.
MCC950/CRID3 inhibits the inflammasome in wild-type but not
Nlrp3L351P macrophages
Considering our observation that CAPS-associated Nlrp3 mutants escape PAL-CRID3 binding
may have potential implications for treating CAPS with MCC950/CRID3, we sought to func-
tionally validate these results with MCC950/CRID3 in the reported Nlrp3L351P CAPS model
[23]. To this end, mice that were homozygous for the Nlrp3L351P allele were bred to transgenic
mice that hemizygously expressed the tamoxifen-inducible Cre recombinase-estrogen receptor
(Cre-ERT2) fusion gene (CreT) [24]. Following tamoxifen treatment and excision of the floxed
neomycin resistance cassette, BMDMs of the resulting Nlrp3L351P/+CreT+ mice expressed
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Fig 2. PAL-CRID3 binding requires an intact (d)ATP-binding pocket and fails to bind CAPS-associated NLRP3 mutants. (A) Schematic diagram of NLRP3
depicting the different domains used in this study. (B) HEK293T cells transfected with the indicated plasmids were incubated with PAL-CRID3 in the absence or
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Nlrp3 from both the wild-type and Nlrp3L351P alleles. Macrophages from Cre-ERT2–negative
littermates (Nlrp3L351P/+CreT−), which only express Nlrp3 from the wild-type allele, were used
as controls in these experiments.
Culture media of LPS-stimulated Nlrp3L351P/+CreT+ macrophages contained significant lev-
els of IL-1β (Fig 3A and S2 Data) and IL-18 (Fig 3B and S2 Data), which were associated with
marked maturation of Casp1 and IL-1β in cell lysates (Fig 3C). As reported [23], these LPS-
induced inflammasome responses were driven by the CAPS-associated Nlrp3L351P allele
because Nlrp3L351P/+CreT− BMDMs failed to secrete detectable levels of IL-1β (Fig 3A and S2
Data) and IL-18 (Fig 3B and S2 Data) and did not contain mature Casp1 and IL-1β in their cell
lysates (Fig 3C). Consistent with our previous results that CAPS-associated Nlrp3L351P escaped
PAL-CRID3 binding, we found that MCC950/CRID3 failed to inhibit the above inflamma-
some responses driven by the Nlrp3L351P allele. We confirmed that MCC950/CRID3 was active
against wild-type NLRP3 because it abolished levels of LPS+ATP–induced secretion of IL-1β
(Fig 3D and S2 Data) and IL-18 (Fig 3E and S2 Data) in culture media of Nlrp3L351P/+CreT−
BMDMs (which are solely driven by wild-type Nlrp3 in this genotype, given the absence of a
Cre-ERT2 transgene), as well as the concomitant maturation of Casp1 and IL-1β in the corre-
sponding cell lysates (Fig 3F). Similarly, MCC950/CRID3 abolished LPS + nigericin-induced
secretion of IL-1β (Fig 3G and S2 Data) and IL-18 (Fig 3H and S2 Data) and maturation of
Casp1 and IL-1β by Nlrp3L351P/+CreT− macrophages (Fig 3I). In marked contrast, LPS + ATP-
and LPS + nigericin-induced inflammasome responses were insensitive to MCC950/CRID3
blockade in Nlrp3L351P/+CreT+ BMDMs that express both the Nlrp3L351P allele and wild-type
Nlrp3 (Fig 3D–3I and S2 Data). Together, these results establish that the CAPS-associated
Nlrp3L351P allele is insensitive to MCC950/CRID3 inhibition.
MCC950/CRID3 inhibition of inflammasome responses in Nlrp3A350V
macrophages
Unlike for Nlrp3L351P, labeling of Nlrp3A350V by PAL-CRID3 was not significantly impacted
by the mutation (Fig 2E and 2F and S3 Data). To address whether this was mirrored by potent
inhibition of Nlrp3A350V-driven inflammasome responses by MCC950/CRID3, mice that were
homozygous for the previously reported Nlrp3A350V allele were bred to the CreT transgenic
mice described above. Following tamoxifen treatment and excision of the floxed neomycin
resistance cassette, BMDMs of the resulting Nlrp3A350V/+CreT+ mice expressed Nlrp3 from
both the wild-type and Nlrp3A350V alleles. BMDMs from CreT-negative littermates
(Nlrp3A350V/+CreT−), which only express Nlrp3 from the wild-type allele, were used as controls
in these experiments.
Like Nlrp3L351P/+CreT+ BMDMs (Fig 3A–3C and S2 Data), Nlrp3A350V/+CreT+ macro-
phages that expressed Nlrp3A350V secreted high levels of IL-1β (Fig 4A and S3 Data) and IL-18
(Fig 4B and S3 Data) in response to LPS stimulation alone. This was accompanied by proteo-
lytic maturation of Casp1 and proIL-1β, as demonstrated by immunoblot analysis (Fig 4C). As
expected, these responses were absent from LPS-stimulated Nlrp3A350V/+CreT− BMDMs that
expressed wild-type Nlrp3 only (Fig 4A–4C and S3 Data). MCC950/CRID3 potently inhibited
presence of free MCC950/CRID3 and subsequently irradiated. After cells are lysed, click chemistry is performed, and lysates are assayed by TAMRA imaging and
by immunoblot analysis with the indicated antibodies. (C–F) HEK293T cells were transfected with the indicated plasmids and incubated with 1 μM PAL-CRID3,
unless indicated otherwise, and subsequently irradiated. After cell lysis, click chemistry was performed, and lysates were assayed by TAMRA imaging and by
immunoblot analysis with the indicated antibodies. CAPS, cryopryin-associated periodic syndrome; CRID, Cytokine Release Inhibitory Drug; HD, helical
domain; HEK, human embryonic kidney; LRR, leucine-rich repeat; NBD, nucleotide-binding domain; NLR, NBD- and LRR-containing; NLRP3, NLR family,
pyrin-domain–containing 3; NOD, nucleotide-binding oligomerization domain; PAL, photoaffinity labeling; PYD, Pyrin domain; TAMRA,
5-carboxytetramethylrhodamine; WB, western blot; WHD, winged helix domain.
https://doi.org/10.1371/journal.pbio.3000354.g002
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LPS-induced IL-1β (Fig 4A and S3 Data) and IL-18 (Fig 4B and S3 Data) secretion and
Nlrp3A350V-driven cleavage of Casp1 and IL-1β (Fig 4C and S3 Data), in marked contrast to
Nlrp3L351P/+CreT+ macrophages that proved insensitive to MCC950/CRID3 blockade (Fig
3A–3C and S2 Data).
LPS + ATP and LPS + nigericin potently triggered IL-1β and IL-18 secretion and matura-
tion of Casp1 and pro-IL-1β from both Nlrp3A350V/+CreT+ and Nlrp3A350V/+CreT− control
BMDMs (Fig 4D–4I and S3 Data). However, whereas MCC950/CRID3 abolished LPS + ATP-
and LPS + nigericin-induced IL-1β secretion from Nlrp3A350V/+CreT− control BMDMs, it
failed to alter secretion of IL-1β from parallelly treated Nlrp3A350V/+CreT+ BMDMs (Fig 4D
and 4G; S3 Data). MCC950/CRID3 also abrogated LPS + ATP- and LPS + nigericin-induced
IL-18 secretion from control Nlrp3A350V/+CreT− BMDMs but only reduced IL-18 secretion
from parallelly stimulated Nlrp3A350V/+CreT+ macrophages by about 50% (Fig 4E and 4H; S3
Data). Aligned with these results, MCC950/CRID3 inhibited LPS + ATP- and LPS + nigericin-
induced cleavage of Casp1 and pro-IL-1β in control Nlrp3A350V/+CreT− BMDMs but not in
Nlrp3A350V/+CreT+ macrophages (Fig 4F and 4I). Together, these results show that although
binding of PAL-CRID3 to Nlrp3A350V was not significantly compromised, the mutation subtly
alters the ability of MCC950/CRID3 to inhibit inflammasome activation in primary macro-
phages, with potent inhibition seen only in response to LPS but not following “signal 2” trig-
gers such as ATP and nigericin.
Inflammasome inhibition in homozygous mutant macrophages
The studies described above were performed in heterozygous macrophages that express both
wild-type and CAPS-associated Nlrp3 mutants. Considering that the Nlrp3 NACHT region facili-
tates Nlrp3 oligomerization, we decided to further assess MCC950/CRID3 responses in macro-
phages that uniquely express the CAPS-associated Nlrp3 mutants in the absence of wild-type
Nlrp3. To do so, we transduced wild-type, Nlrp3A350V/A350V, and Nlrp3L351P/L351P BMDMs with
Cre-recombinase–expressing lentiviruses to excise the neomycin resistance cassette that is placed
upstream of the Nlrp3 mutation and to allow expression of the CAPS-associated Nlrp3 mutants.
As expected, wild-type macrophages failed to secrete IL-1β and IL-18 in response to LPS
alone, and MCC950/CRID3 abolished secretion of IL-1β and IL-18 when wild-type BMDMs
were stimulated with LPS + ATP or LPS + nigericin (Fig 5A and 5B; S4 Data). LPS stimulation
alone was sufficient to induce extracellular release of IL-1β and IL-18 from homozygous
Nlrp3L351P/L351P and Nlrp3A350V/A350V macrophages (Fig 5C–5F; S4 Data). MCC950/CRID3
inhibited Nlrp3L351P-induced secretion of IL-1β and IL-18 neither in response to LPS alone
nor when combined with “signal 2” agents ATP or nigericin (Fig 5C and 5D; S4 Data),
unequivocally establishing that Nlrp3L351P-induced inflammasome activation is insensitive to
MCC950/CRID3 blockade. Consistent with our previous results in heterozygous Nlrp3A350V
mutant macrophages, MCC950/CRID3 partially inhibited LPS-induced IL-1β and IL-18 levels
Fig 3. MCC950/CRID3 inhibits the inflammasome in wild-type but not Nlrp3L351P macrophages. (A–C) BMDMs from tamoxifen-treated Nlrp3L351P/+CreT−
and Nlrp3L351P/+ CreT+ mice were left untreated (Ctrl) or treated with LPS in absence or presence of MCC950/CRID3. Supernatants were analyzed for IL-1β (A)
and IL-18 (B) secretion and lysates were immunoblotted for Casp1 and IL-1β (C). (D–F) BMDMs from tamoxifen-treated Nlrp3L351P/+CreT− and Nlrp3L351P/
+CreT+ mice were left untreated (Ctrl) or primed with LPS and stimulated with ATP in absence or presence of MCC950/CRID3. Supernatants were analyzed for
IL-1β (D) and IL-18 (E) secretion and lysates were immunoblotted for Casp1 and IL-1β (F). (G–I) BMDMs from tamoxifen-treated Nlrp3L351P/+CreT− and
Nlrp3L351P/+CreT+ mice were left untreated (Ctrl) or primed with LPS and stimulated with Nig in absence or presence of MCC950/CRID3. Supernatants were
analyzed for IL-1β (G) and IL-18 (H) secretion, and lysates were immunoblotted for Casp1 and IL-1β (I). The numerical values underlying Fig 3A, 3B, 3D, 3E,
3G, and 3H can be found in S2 Data. Graphs show mean ± SD of triplicate wells and represent three independent experiments. BMDM, bone-marrow–derived
macrophage; Casp1, caspase-1; Cre-ERT2, Cre recombinase-estrogen receptor fusion protein; CreT, Cre-ERT2 fusion gene; CRID, Cytokine Release Inhibitory
Drug; Ctrl, control; IL, interleukin; LPS, lipopolysaccharides; LRR, leucine-rich repeat; NBD, nucleotide-binding domain; Nig, nigericin; NLR, NBD- and LRR-
containing; NLRP3, NLR family, pyrin-domain–containing 3.
https://doi.org/10.1371/journal.pbio.3000354.g003
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in culture supernatants of homozygous Nlrp3A350V/A350V macrophages, but this was not
observed in response to LPS + ATP and LPS + nigericin (Fig 5E and 5F; S4 Data).
In vivo MCC950/CRID3 inhibition of inflammasome activation in CAPS
disease models
Myeloid-specific expression of the Nlrp3L351P and Nlrp3A350V alleles in knock-in mice was
shown to drive systemic inflammation accompanied by, respectively, embryonic and perinatal
lethality that in both cases required Nlrp3 inflammasome activation [23]. To seek further vali-
dation of the notion that the Nlrp3L351P mutations escape MCC950/CRID3 inhibition, we next
investigated how MCC950/CRID3 treatment impacts on the CAPS phenotype of Nlrp3L351P/+
CreT+ mice. As expected, serum levels of IL-1β, IL-18, and IL-6 were significantly increased in
Nlrp3L351P/+CreT+ mice three days after tamoxifen dosing relative to the basal levels of tamoxi-
fen-treated Nlrp3L351P/+CreT− littermate mice (S1A–S1C Fig and S7 Data). Moreover, tamoxi-
fen treatment resulted in Nlrp3L351P/+CreT+ mice presenting with substantial weight loss and
mortality, with all mice being lost or requiring termination because of humane endpoints
within 5 days after commencing tamoxifen treatment (Fig 6A and 6B; S5 Data). As a control,
tamoxifen administration did not alter body weight or survival of Nlrp3L351P/+CreT− mice (Fig
6A and 6B; S5 Data). Daily intraperitoneal (IP) injection of MCC950/CRID3 did not rescue
body weight loss or mortality rates of Nlrp3L351P/+CreT+ mice, suggesting that MCC950/
CRID3 failed to inhibit in vivo Nlrp3L351P-induced inflammasome activation (Fig 6A and 6B;
S5 Data). In agreement, IP dosing of MCC950/CRID3 failed to reduce tamoxifen-induced
levels of IL-1β, IL-18, and IL-6 in serum of Nlrp3L351P/+CreT+ mice (Fig 6C–6E; S5 Data).
Thus, the CAPS-associated L351P mutation renders Nlrp3 insensitive to MCC950/CRID3
inhibition.
Our results in Nlrp3A350V macrophages showed that this mutation subtly altered the ability
of MCC950/CRID3 to inhibit inflammasome activation with potent inhibition seen only in
response to LPS but not following “signal 2” triggers such as ATP and nigericin (Fig 4). To
determine how this translates to the in vivo disease setting, we analyzed circulating cytokine
levels and body weight loss of Nlrp3A350V/+CreT+ mice following tamoxifen administration.
Although there was a trend towards increased serum levels of IL-1β, the low measured concen-
trations did not reach statistical significance compared to tamoxifen-treated Nlrp3A350V/+
CreT− littermate mice (S1D Fig and S7 Data). However, serum concentrations of IL-18 and
IL-6 were significantly elevated in tamoxifen-treated Nlrp3A350V/+CreT+ mice relative to
Nlrp3A350V/+CreT− littermates (S1E and S1F; S7 Data). Nevertheless, levels of the latter cyto-
kines were on average 10- to 20-fold lower than seen in tamoxifen-treated Nlrp3L351P/+CreT+
mice, a finding that is consistent with the milder pathology and the lack of mortality associated
with the Nlrp3A350V/+CreT+ CAPS model. Consistent with published findings [25], Nlrp3A350V/+
CreT+ mice developed an inflammatory phenotype characterized by a steady weight loss of up
Fig 4. MCC950/CRID3 inhibition of inflammasome responses in Nlrp3A350V macrophages. (A–C) BMDMs from tamoxifen-treated Nlrp3A350V/+CreT− and
Nlrp3A350V/+CreT+ mice were left untreated (Ctrl) or treated with LPS in absence or presence of MCC950/CRID3. Supernatants were analyzed for IL-1β (A) and
IL-18 (B) secretion, and lysates were immunoblotted for Casp1 and IL-1β (C). (D–F) BMDMs from tamoxifen-treated Nlrp3A350V/+CreT− and Nlrp3A350V/+CreT+
mice were left untreated (Ctrl) or primed with LPS and stimulated with ATP in absence or presence of MCC950/CRID3. Supernatants were analyzed for IL-1β
(D) and IL-18 (E) secretion, and lysates were immunoblotted for Casp1 and IL-1β (F). (G–I) BMDMs from tamoxifen-treated Nlrp3A350V/+CreT− and Nlrp3A350V/
+CreT+ mice were left untreated (Ctrl) or primed with LPS and stimulated with Nig in absence or presence of MCC950/CRID3. Supernatants were analyzed for
IL-1β (G) and IL-18 (H) secretion, and lysates were immunoblotted for Casp1 and IL-1β (I). The numerical values underlying Fig 4A, 4B, 4D, 4E, 4G, and 4H can
be found in S3 Data. Graphs show mean ± SD of triplicate wells and represent three independent experiments. BMDM, bone-marrow–derived macrophage;
Casp1, caspase-1; Cre-ERT2, Cre recombinase-estrogen receptor fusion protein; CreT, Cre-ERT2 fusion gene; CRID, Cytokine Release Inhibitory Drug; Ctrl,
control; IL, interleukin; LPS, lipopolysaccharides; LRR, leucine-rich repeat; NBD, nucleotide-binding domain; Nig, nigericin; NLR, NBD- and LRR-containing;
NLRP3, NLR family, pyrin-domain–containing 3.
https://doi.org/10.1371/journal.pbio.3000354.g004
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Fig 5. Inflammasome inhibition in homozygous mutant macrophages. (A–F) Wild-type (A–B), Nlrp3L351P/L351P (C–D), or Nlrp3A350V/A350V (E–F) BMDMs
that were transduced with a Cre-recombinase–expressing lentiviral vector were left unstimulated (Ctrl) or stimulated with LPS and then left untreated or treated
with ATP or Nig in absence or presence of MCC950/CRID3. Supernatants were analyzed for IL-1β (A,C,E) and IL-18 (B,D,F) secretion. The numerical values
underlying Fig 5A–5F can be found in S4 Data. Graphs show mean ± SD of triplicate wells and represent three independent experiments. BMDM, bone-marrow–
derived macrophage; Cre, Cre recombinase; CRID, Cytokine Release Inhibitory Drug; Ctrl, control; IL, interleukin; LPS, lipopolysaccharides; LRR, leucine-rich
repeat; NBD, nucleotide-binding domain; Nig, nigericin; NLR, NBD- and LRR-containing; NLRP3, NLR family, pyrin-domain–containing 3.
https://doi.org/10.1371/journal.pbio.3000354.g005
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to 20% within 27 days (Fig 6F and S5 Data). Notably, daily IP dosing of MCC950/CRID3 stabi-
lized Nlrp3A350V-mediated body weight loss in Nlrp3A350V/+CreT+ mice relative to PBS-treated
controls, although differences were small and MCC950/CRID3-treated mice failed to thrive and
gain weight like the Nlrp3A350V/+CreT− control group (Fig 6F and S5 Data). In agreement,
MCC950/CRID3 had a mild or no effect on circulating levels of the systemic inflammatory
markers IL-18 (Fig 6G and S5 Data) and IL-6 (Fig 6H and S5 Data), respectively. Together,
these results establish that MCC950/CRID3 has a weak but measurable effect on Nlrp3A350V-
induced inflammasomopathy in adult mice.
MCC950/CRID3 inhibition of LPS-induced cytokines in CAPS mutant mice
To complement the chronic CAPS disease models described above, we next evaluated the
potency of MCC950/CRID3 in inhibiting acute Nlrp3-dependent inflammasome responses by
subjecting wild-type and CAPS mutant mice to LPS-induced endotoxemia and probing the
effect of MCC950/CRID3 on well-documented Nlrp3-dependent readouts such as LPS-
induced elevation of serum levels of IL-1β and IL-18 [26].
As expected, Nlrp3L351P/+CreT− control mice presented with increased serum levels of IL-
1β and IL-18 3 h after LPS challenge (Fig 7A and 7B and S6 Data). MCC950/CRID3 substan-
tially curbed circulating IL-1β and IL-18 levels in this control group (Fig 7A and 7B), consis-
tent with reported findings in LPS-challenged C57BL/6 mice [15]. Contrastingly, serum levels
of IL-1β and IL-18 in LPS-dosed Nlrp3L351P/+CreT+ mice were not significantly impacted by
MCC950/CRID3 relative to PBS-treated Nlrp3L351P/+CreT+ littermates (Fig 7C and 7D and S6
Data).
LPS challenge increased serum concentrations of IL-1β and IL-18 in Nlrp3A350V/+CreT−
control mice, which were inhibited by MCC950/CRID3 (Fig 7E and 7F and S6 Data) similarly
to its effect on LPS-treated Nlrp3L351P/+CreT− control mice (Fig 7A and 7B and S6 Data). This
is not unexpected because both genotypes express solely wild-type Nlrp3 in the absence of
Cre-recombinase–mediated excision of the neomycin resistance cassette that disrupts expres-
sion of the respective CAPS-associated Nlrp3 mutants. However, in marked contrast to
Nlrp3L351P-expressing CreT+ mice (Fig 7C and 7D and S6 Data), MCC950/CRID3 markedly
curbed circulating concentrations of IL-1β and IL-18 in Nlrp3A350V-expressing CreT+ mice
(Fig 7G and 7H). These results confirm that MCC950/CRID3 potently inhibits inflammasome
activation by wild-type Nlrp3 and the MWS-associated Nlrp3A350V mutant but not the FCAS-
associated Nlrp3L351P mutant.
Discussion
Activation of the NLRP3 inflammasome has been observed in many diseases, and its central
role in driving pathological inflammation renders it an attractive target for therapeutic inter-
vention [10]. Gain-of-function mutations in NLRP3 cause hereditary periodic fever syndromes
Fig 6. In vivo MCC950/CRID3 inhibition of inflammasome activation in CAPS disease models. (A–B) Growth (A) and survival (B) curves of tamoxifen-
treated Nlrp3L351P/+CreT+ that received daily injections of PBS (n = 6) or 50 mg kg−1 MCC950/CRID3 (n = 6) and of tamoxifen-treated CreT− littermates
(n = 6). (C–E) IL-1β (C), IL-18 (D), and IL-6 (E) cytokine levels in serum obtained at day 4 from tamoxifen-treated Nlrp3A350V/+CreT+ mice that received
daily injections of PBS (n = 6) or MCC950/CRID3 (n = 6). Serum of tamoxifen-treated CreT− littermates injected with PBS (n = 8) or MCC950/CRID3
(n = 2) was used as control. (F) Growth curves of tamoxifen-treated Nlrp3A350V/+CreT+ that received daily injections of PBS (n = 6) or 50 mg kg−1 MCC950/
CRID3 (n = 7) and of tamoxifen-treated CreT− littermates (n = 6). (G–H) IL-18 (G) and IL-6 (H) cytokine analysis of serum obtained at day 4 from
tamoxifen-treated Nlrp3A350V/+CreT+ mice that received daily injections of PBS (n = 7) or MCC950/CRID3 (n = 8). Serum of tamoxifen-treated CreT−
littermates treated with PBS (n = 8) or MCC950/CRID3 (n = 5) was used as control. The numerical values underlying Fig 6A–6H can be found in S5 Data.
Graphs show mean ± SD and represent two independent experiments. CAPS, cryopyrin-associated periodic syndrome; Cre-ERT2, Cre recombinase-
estrogen receptor fusion protein; CreT, Cre-ERT2 fusion gene; CRID, Cytokine Release Inhibitory Drug; IL, interleukin; LRR, leucine-rich repeat; NBD,
nucleotide-binding domain; NLR, NBD- and LRR-containing; NLRP3, NLR family, pyrin-domain–containing 3; ns, not significant.
https://doi.org/10.1371/journal.pbio.3000354.g006
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that are collectively referred to as CAPS, and these patients are currently treated with biologics
that target secreted IL-1 [12]. As reported [27], chronic IL-1 blockade increases the risk for
fatal infections and sepsis, suggesting that selective targeting of the NLRP3 inflammasome may
potentially be a safer and more efficacious therapeutic strategy because it would block produc-
tion of the central inflammatory mechanisms that contribute to inflammatory pathology while
at the same time keeping nontargeted inflammasomes available to produce IL-1β to cope with
infections.
Early studies with the sulfonylurea compound glyburide provided proof of concept that
small molecules may selectively inhibit the NLRP3 inflammasome pathway without interfering
with other inflammasomes [13]. Subsequently, several additional compounds have been
reported to specifically inhibit the NLRP3 inflammasome pathway, but the majority of these
agents have weak activity against the NLRP3 inflammasome pathway (μM IC50 concentra-
tions) and may target nuclear factor κB (NF-κB) signaling and other immune pathways
(reviewed in [10]). MCC950/CRID3 is structurally related to glyburide [14,15] and is consid-
ered the most potent and selective inhibitor of NLRP3 inflammasome signaling reported to
date. There is substantial interest in developing this chemical scaffold for the treatment of
CAPS and other diseases. However, these efforts are constrained by the lack of insight into the
molecular target and mechanism by which MCC950/CRID3 and related sulfonylurea mole-
cules inhibit activation of the NLRP3 inflammasome pathway.
Making use of PAL and iBody technology as complementary chemical biology approaches,
we here identified NLRP3 as the physical target of MCC950/CRID3. We further mapped the
binding pocket to the central NACHT domain of NLRP3 and showed that PAL required an
intact ATP/dATP binding pocket. This suggests that binding may occur at the nucleotide-
binding/hydrolysis pocket of NLRP3. This hypothesis is consistent with and extends results
from two recent reports that suggest the adjacent Walker B motif as the putative binding site
of MCC950/CRID3 [28,29]. However, it cannot be excluded that mutations in the Walker A/B
motifs may cause long-distance conformational changes that distort a more remote MCC950/
CRID3 binding pocket elsewhere in the NACHT domain. Notable in this regard is our obser-
vation that a randomly selected panel of 6 CAPS-associated gain-of-function mutations in
human NLRP3 all failed to be labeled by our PAL probe, further supporting the notion that the
sulfonylurea CRID binding pocket is highly sensitive for conformational changes in the pro-
tein that are imposed by mutations. Thus, further insight into the MCC950/CRID3 binding
pocket and the molecular mechanism by which MCC950/CRID3 inhibits NLRP3 activation
will likely require high-resolution structural analysis.
Considering the potential implications of these findings for treating CAPS with MCC950/
CRID3-based therapies, we evaluated the functional impact of MCC950/CRID3 in two
reported CAPS models [23]. When knocked into the murine Nlrp3 sequence, the FCAS-asso-
ciated Nlrp3L351P mutant (corresponding to human L353P) also failed to bind to PAL-CRID3.
Fig 7. MCC950/CRID3 inhibition of LPS-induced cytokines in CAPS mutant mice. (A–B) At day 3 post-tamoxifen, Nlrp3L351P/+CreT−
mice were pretreated with PBS (n = 12) or MCC950/CRID3 (n = 13) and subsequently challenged with LPS for 3 h. Serum levels of IL-1β
(A) and IL-18 (B) were analyzed before and after LPS administration. (C–D) At day 3 post-tamoxifen, Nlrp3L351P/+CreT+ mice were
pretreated with PBS (n = 11) or MCC950/CRID3 (n = 14) and subsequently challenged with LPS for 3 h. Serum levels of IL-1β (C) and IL-18
(D) were analyzed before and after LPS administration. (E–F) At day 3 post-tamoxifen, Nlrp3A350V/+CreT− mice were pretreated with PBS
(n = 15) or MCC950/CRID3 (n = 15) and subsequently challenged with LPS for 3 h. Serum levels of IL-1β (E) and IL-18 (F) were analyzed
before and after LPS administration. (G–H) At day 3 post-tamoxifen, Nlrp3A350V/+CreT+ mice were pretreated with PBS (n = 15) or
MCC950/CRID3 (n = 15) and subsequently injected with LPS for 3 h. Serum levels of IL-1β (G) and IL-18 (H) were analyzed before and
after LPS challenge. The numerical values underlying Fig 7A–7H can be found in S6 Data. Graphs show mean ± SD and represent two
independent experiments. CAPS, cryopyrin-associated periodic syndrome; Cre-ERT2, Cre recombinase-estrogen receptor fusion protein;
CreT, Cre-ERT2 fusion gene; CRID, Cytokine Release Inhibitory Drug; IL, interleukin; LPS, lipopolysaccharides; LRR, leucine-rich repeat;
NBD, nucleotide-binding domain; NLR, NBD- and LRR-containing; NLRP3, NLR family, pyrin-domain–containing 3; ns, not significant.
https://doi.org/10.1371/journal.pbio.3000354.g007
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Consistent with these results, our analysis of both ex vivo-stimulated mutant macrophages
and in vivo CAPS and endotoxemia models unequivocally established that MCC950/CRID3
potently inhibits inflammasome activation by wild-type Nlrp3 but not the FCAS-associated
Nlrp3L351P mutant. Surprisingly, however, we found that labeling by PAL-CRID3 to the
MWS-linked Nlrp3A350V mutant (corresponding to A352V in human NLRP3) was not signifi-
cantly impacted by the mutation. MCC950/CRID3 partially inhibited LPS-induced IL-1β
and IL-18 secretion from macrophages that homozygously or heterozygously expressed the
Nlrp3A350V mutant, but inhibition of the Nlrp3A350V inflammasome was completely lost in
response to “signal 2” agents ATP and nigericin. Consequently, MCC950/CRID3 significantly
lowered IL-1β and IL-18 levels in serum of LPS-challenged Nlrp3A350V knock-in mice, whereas
it provided only limited protection against chronic CAPS mutation-driven body weight loss.
The Cre-ERT2 recombinase expression system used with our CAPS disease models allows for
controlled ubiquitous tissue expression of the mutant Nlrp3 knock-in allele upon tamoxifen
treatment in adult animals. Expression of the Nlrp3A350V allele does not induce lethality in
adult mice under these conditions. However, another study [15] that relied on lysosome
M-Cre–driven expression of the Nlrp3A350V allele in cells of the myeloid lineage observed
that MCC950/CRID3 rescued neonatal lethality, consistent with our observation that the
Nlrp3A350V mutant retained sensitivity to MCC950/CRID3 inhibition. This report also sug-
gested MCC950/CRID3 inhibits LPS-induced IL-1β processing in peripheral blood mononu-
clear cells (PBMCs) from MWS patients. Another study showed that unlike samples from
healthy controls, LPS- and LPS + ATP-induced IL-1β secretion from whole-blood samples of
genetically defined CAPS patients resisted MCC950/CRID3 inhibition [30], which is consis-
tent with our results suggesting that MCC950/CRID3-based therapies may effectively treat
inflammation driven by wild-type NLRP3 but may be markedly less effective in CAPS patients.
To conclude, by identifying the molecular target of MCC950/CRID3 in the NLRP3 inflamma-
some pathway and by evaluating its ability to inhibit CAPS mutant variants, the findings pre-
sented here provide a mechanistic framework for advancing therapeutic development of this
chemical scaffold and for understanding its therapeutic potential in patients.
Material and methods
Ethics statement
All animal experiments were conducted with permission of the ethical committee on labora-
tory animal welfare of Ghent University. All procedures were performed in accordance with
the guidelines and regulations associated with protocol number EC2017-090.
Synthesis of PAL-CRID3
Detailed experimental procedures for the synthesis of PAL-CRID3 are provided in the Supple-
mentary Data section (S1 Text).
Synthesis of iBody conjugates
Experimental procedures for the preparation of the iBody conjugates have been described by
[18], and details for the production of MCC950/CRID3 iBody conjugates are provided in the
Supplementary Data section.
iMac and BMDM culture
Bone marrow cells from C57BL/6 mice were immortalized as described previously [31]. Pri-
mary bone marrow or iMac progenitor cells were differentiated in DMEM or IMDM
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supplemented with 10% endotoxin-free heat-inactivated fetal bovine serum, 20%–30% L929-
conditioned medium, 100 U ml−1 penicillin, and 100 mg ml−1 streptomycin for 5–6 days at
37˚C in a humidified atmosphere containing 5% CO2. 6 days later, cells were collected and
seeded at a density of 8.5 × 105 cells per well in 12-well plates in IMDM containing 10% heat-
inactivated FBS and 1% nonessential amino acids in the presence of antibiotics. The next
day, BMDMs were either left untreated or treated with 1 μM MCC950/CRID3 (S7809; Selleck-
chem, Houston, TX, USA) and then stimulated with 0.5 μg ml−1 ultrapure LPS from Salmo-
nella minnesota (tlrl-smlps; Invivogen, San Diego, CA, USA) for 3 h followed by 5 mM ATP
(10519987001; Roche, Basel, Switzerland) or 20 μM nigericin (N-7143; Sigma-Aldrich,
St. Louis, MO, USA) for 45 min. For the dose–response analysis of PAL-CRID3 and MCC950/
CRID3, adherent BMDMs or differentiated iMac were seeded at 1 × 105 cells per well in
96-well plates and cultured overnight. The following day, medium was removed and replaced
with OPTI-MEM I (Thermo Fisher Scientific, Waltham, MA, USA) containing 1 μg mL−1
Pam3CSK4 (Invivogen). Postpriming (5–6 h later), cells were incubated with DMSO (1:1,000),
MCC950/CRID3 (0.001–100 μM), or PAL-CRID3 (0.001–100 μM) for 30 min and then stimu-
lated with 5 μg mL−1 nigericin (Invivogen) for 30 min.
Transfections
HEK293T cells were maintained in DMEM media supplemented with 10% fetal bovine serum.
HEK293T cells were transfected in 12-well plates with Lipofectamine 2000 (Thermo Fisher Sci-
entific) according to manufacturer’s instructions. All constructs, including NLRP3 cDNAs
were synthesized and subcloned into pCDNA3 (+) Zeo (Thermo Fisher Scientific).
Photolabeling
Transfected HEK293T were incubated with DMSO or photo probe PAL-CRID3 (1 μM unless
stated otherwise) for 30 min at 37˚C in 500 μL OPTI-MEM. For competition experiments with
free MCC950/CRID3, 10 μM MCC950/CRID3 was added 30 min prior. Photolabeling and
click chemistry experiments were performed as described with slight modification [32].
Briefly, cells were washed once with ice-cold PBS and UV irradiated at 365 nm (100 W) on ice
for 10 min. Cells were washed once with ice-cold PBS and frozen at −80˚C. Lysis buffer was
added (40 mM HEPES, 140 mM NaCl, 0.1% Triton-X-100, Roche EDTA-free complete prote-
ase inhibitor), and cells were detached with a cell scraper. Crude lysates were clarified by cen-
trifugation (30 min at 14,000 rpm, 4˚C). For click chemistry, lysates (20 μL) were incubated
with 5 μL freshly mixed click cocktail composed of 1.7 mM TBTA in 1:4 DMSO/t-BuOH
(1.5 μL), 5 mM TAMRA-N3 (0.3 μL), 50 mM TCEP (0.5 μL, freshly prepared), and 10% SDS
(2.7 μL). Then, 50 mM CuSO4 (0.5 μL), was added, and reactions were incubated for 1 hr at
RT with gentle mixing. Reactions were quenched with 4× LDS buffer and separated by
SDS-PAGE. Gels were scanned for TAMRA fluorescence on a Typhoon Trio scanner (GE Life
Sciences, Chicago, IL, USA).
Mice
Nlrp3−/− [33] and NLRC43xFlag [21] were described. The CAPS models Nlrp3A350VneoR and
Nlrp3L351PneoR [23] and R26-CreERT2 mice [24] (B6.129-Gt(ROSA)26Sortm1(cre/ERT2)Tyj/J,
Jax stock number: 008463; here abbreviated as CreT) were originally obtained from The Jack-
son Laboratory (Bar Harbor, ME, USA), and colonies were further maintained at the animal
facilities of Ghent University. Mice were housed in individually ventilated cages and kept
under pathogen-free conditions at animal facilities of Ghent University. Nlrp3A350VneoR
and Nlrp3L351PneoR, which are homozygous for the mutated Nlrp3 gene, were bred to the
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tamoxifen-inducible Cre line R26-CreERT2 mice to generate Nlrp3A350neoR/+R26-CreERT2Tg+
(herein referred to as Nlrp3A350V/+CreT+) and Nlrp3L351PneoR/+R26-CreERT2Tg+ mice (here
referred to as Nlrp3L351P/+CreT+), in which expression of mutant Nlrp3 is induced through
administration of tamoxifen. 4- to 5-week–old mice received at two consecutive days tamoxi-
fen (T5648, Sigma-Aldrich, dissolved in 1:9 ethanol/corn oil (C-8267, Sigma-Aldrich) at 50 mg
ml−1) through oral gavage at a dose of 5 mg tamoxifen per mouse per day. On day 3, tamoxifen
was administered through diet (Teklad Global 16% Rodent Diet with 400 ppm tamoxifen per
kg; Harlan, Horst, The Netherlands).
In vivo LPS challenge
6- to 12-week–old mice were intraperitoneally injected with PBS or 50 mg kg−1 MCC950/
CRID3, 30 minutes before being challenged with 40 mg kg−1 LPS (Escherichia coli, serotype
0111:B4, L-2630; Sigma-Aldrich). Mice were euthanized 3 h after LPS challenge for blood col-
lection. At the 0 h time point before LPS challenge, blood was collected by retro-orbital
bleeding.
iBody immunoprecipitation
12 × 106 BMDMs were harvested, and cells were washed in PBS and lysed by three cycles of
freeze/thawing in PBS with 0.09% NP40 supplemented with complete protease inhibitor cock-
tail (4693159001; Roche Applied Science). Cell lysates were clarified by centrifugation at
14,000 rpm for 20 minutes, and supernatants were subsequently incubated with 1 μM of the
indicated iBody at RT for 10 minutes. Then prewashed streptavidin conjugated beads were
added, followed by overnight incubation at 4˚C. The next day, beads were washed 3 times in
PBS with 0.09% NP40 buffer, and biotinylated proteins were eluted in Laemmli buffer and ana-
lyzed by western blot.
Lentiviral Cre transduction
To induce lentivirus production, the lentiviral GFP.Cre empty vector (20781; Addgene,
Watertown, MA, USA), together with second-generation packaging vector psPAX2 (12260;
Addgene) and VSV-G–expressing envelope plasmid pCMV-VSV-G (8454; Addgene), was
transfected into HEK293T cells using jetPRIME transfection reagent (114–15; PolyPlus-trans-
fection, Illkirch, France). Lentiviral-particle–containing medium was collected 48 h after trans-
fection, filtered using a 0.45 μm filter, and incubated with harvested bone marrow. 6 days later,
differentiated macrophages were collected, washed, and seeded into 12-well cell culture plates
prior to stimulation.
Cytokine analysis
Cytokine levels in culture medium and serum were determined by magnetic-bead–based mul-
tiplex assay using Luminex technology (Bio-Rad, Hercules, CA, USA), IL-1β ELISA (R&D Sys-
tems, Minneapolis, MN, USA) and mouse IL-1β tissue culture kit (Meso Scale Discovery,
Rockville, MD, USA) according to the manufacturers’ instructions.
Western blotting
Cell lysates were prepared using lysis buffer containing 20 mM Tris HCl (pH 7.4), 200 mM
NaCl, and 1% NP-40. Samples for detection of Casp1 and IL-1β processing were prepared by
combining cell lysates with culture supernatants. Samples were denatured in Laemmli buffer
and boiled at 95˚C for 10 min. SDS-PAGE–separated proteins were transferred to PVDF
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membranes and immunoblotted with primary antibodies against Casp1 (AG-20B-0042-C100;
Adipogen, Liestal, Switzerland), IL-1β (GTX74034; Genetex, Irvine, CA, USA), Flag-tag (Flag
M2-Peroxidase; Sigma-Aldrich) and actin (AC15; Novus Biologicals, Centennial, CO, USA).
Horseradish-peroxidase–conjugated goat anti-mouse (115-035-146; Jackson Immunoresearch
Laboratories, West Grove, PA, USA) or anti-rabbit secondary antibody (111-035-144; Jackson
Immunoresearch Laboratories) was used to detect proteins by enhanced chemiluminescence
(Thermo Fisher Scientific).
Statistical analysis
GraphPad Prism 5.0 software was used for data analysis. For survival studies, data were com-
pared by log-rank (Mantel–Cox) test. Two-way ANOVA tests were used to assess body weight
differences between groups. Unpaired two-tailed Student t test was applied to compare cyto-
kine serum levels. Data are shown as mean with standard deviation. P< 0.05 was considered
to indicate statistical significance.
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